A prospective study to assess the effect of adalimumab on cardiovascular biomarkers in participants with severe chronic plaque psoriasis

Not Applicable

• Conditions: Chronic plaque psoriasis; Skin - Dermatological conditions; Inflammatory and Immune System - Other inflammatory or immune system disorders

• Registration Number: ACTRN12613000419763
• Lead Sponsor: Dr Anna Braue

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2013-04-15
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: ot yet recruiting
• Sex: All
• Target Recruitment: 15

Inclusion Criteria

Patient who has had severe chronic plaque psoriasis for at least 6 months with no previous exposure to biologics, and is eligible for biologics as per Australian PBS requirements and has been selected to start adalimumab by a dermatologist

Exclusion Criteria

Patients not starting on adalimumab as their first biological agent or has had prior biologic treatment

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
To determine whether there are potential beneficial effects of TNF-inhibition on endothelial function using an EndoPAT [12 weeks post-starting adalimumab]

Secondary Outcome Measures

Name	Time	Method
To determine whether there are beneficial effects of TNF-inhibition on known risk factors such as lipids, insulin resistance and blood pressure with blood tests and sphygmomanometer.<br>[12 weeks post-starting adalimumab];To determine whether ApoB and ApoA-1 testing if a better indicator of cardiovascular abnormalities than the standard measurement of HDL and LDL with blood tests.<br>[12 weeks post-starting adalimumab];To determine whether the psoriasis activity (PASI score) duration correlates with endothelial function impairment using EndoPAT.[12 weeks post-starting adalimumab]